Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

US Oncology Research

Neither a doctor nor a teaching hospital

Research payments

$19,024,041

1,159 payments

Through program year 2025, US Oncology Research is reported as receiving $19,024,041 in research payments, across 1,159 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $556,269 79
2024 Research $2,721,177 413
2023 Research $5,940,110 285
2022 Research $2,837,405 45
2021 Research $2,329,503 78
2020 Research $628,535 80
2019 Research $4,011,042 179

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $7,843,645 70 payments
  2. Acerta Pharma LLC $2,652,385 63 payments
  3. Epizyme, Inc., $1,750,361 542 payments
  4. AstraZeneca UK Limited $1,464,710 16 payments
  5. AstraZeneca Pharmaceuticals LP $1,210,732 41 payments
  6. Genzyme Corporation $1,200,000 1 payment
  7. Celgene Corporation $659,279 12 payments
  8. Pfizer Inc. $539,127 8 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $434,910 9 payments
  10. Aadi Bioscience, Inc. $383,171 105 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Phase III Study, Comparing Nis793 in Combination With Gemcitabine and Nab-Paclitaxel Versus (VS.) Placebo Combined With Gemcitabine and Nab-Paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac) $1,813,558 1 payment
  2. A Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Hematologic Malignancies $1,626,604 2 payments
  3. Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma $1,564,569 457 payments
  4. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $1,538,015 7 payments
  5. a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma $1,250,642 4 payments
  6. Phase III Trial of Adjuvant TC vs TAC in Early Stage HER2-Negative Breast Cancer $1,200,000 1 payment
  7. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $984,480 53 payments
  8. A Randomized, Double-Blind, Phase III Study, Comparing Nis793 in Combination With Gemcitabine and Nab-Paclitaxel Versus (VS.) Placebo Combined With Gemcitabine and Nab-Paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (MPD $830,257 1 payment
  9. Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab VS Placebo in Adjuvant Setting $767,790 10 payments
  10. A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected Tki in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $555,884 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record